Biopharmaceutical company Navidea Biopharmaceuticals Inc (NYSE American:NAVB) reported on Tuesday the completion of its public offering of 8,000,000 common stock.
Under the public offering, the company issued 8,000,000 common stock at a price of USD0.75 per share for aggregate gross proceeds of approximately USD6.0m, before deducting the underwriting discounts, commissions and offering expenses.
Of the total shares in the public offering, about 4,000,000 shares were placed with the company's principal stockholder John Kim Scott, Jr. at the same per share purchase price.
Net proceeds from the offering may be used by the company to fund its research and development programmes, continuing to advance its Phase 2b and Phase 3 clinical trials of Tc99m tilmanocept in patients with rheumatoid arthritis, general working capital purposes as well as other operating expenses.
The company added that H.C. Wainwright & Co acted as sole book-running manager for the offering.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial